DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • Clinical Trials
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • ReMEDy2 Trial
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Media
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Media

DiaMedica Therapeutics Closes 2025 With Strengthened Cash Position And Pipeline Momentum
Mar 31, 2026

TalkMarkets

DiaMedica Therapeutics Closes 2025 With Strengthened Cash Position And Pipeline Momentum

It's a dangerous complication of pregnancy — but a new drug holds promise
Feb 14, 2026

NPR

It's a dangerous complication of pregnancy — but a new drug holds promise

Overcoming Drug Development Obstacles for Some of the Most Challenging Ischemic Conditions
Feb 12, 2026

Xtalks

Overcoming Drug Development Obstacles for Some of the Most Challenging Ischemic Conditions

DDW Winter 2025/2026
Jan 22, 2026

DDW

DDW Winter 2025/2026

More Patient Insight — And Funding— Needed To Advance Preeclampsia Research
Dec 18, 2025

Clinical Leader

More Patient Insight — And Funding— Needed To Advance Preeclampsia Research

Recombinant KLK1: the next step in stroke and preeclampsia treatment
Nov 5, 2025

Drug Target Review

Recombinant KLK1: the next step in stroke and preeclampsia treatment

Spotlight on Women’s Reproductive Health
Oct 23, 2025

Inside Precision Medicine

Spotlight on Women’s Reproductive Health

Diamedica’s DM-199 shows promise for serious pregnancy disorder
Jul 18, 2025

BioWorld

Diamedica’s DM-199 shows promise for serious pregnancy disorder

Diamedica shows early efficacy in preeclampsia — an indication starved for innovation
Jul 17, 2025

BioCentury

Diamedica shows early efficacy in preeclampsia — an indication starved for innovation

DM199 shows promise in phase 2 trial for treating preeclampsia
Jul 17, 2025

Contemporary OBGYN

DM199 shows promise in phase 2 trial for treating preeclampsia

RSS
© 2026 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap